NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC). Molecular characterization of 17 patients with PDAC enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASWT) tumors (4 of 17). These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberrant ERBB receptor-mediated signaling, and pharmacologic ERBB inhibition resulted in clinical improvement and remission of liver metastases in 2 patients with NRG1-rearranged tumors that had proved resistant to standard treatment. Our findings demonstrate that systematic screening of KRASWT tumors for oncogenic fusion genes will substantially improve the therapeutic prospects for a sizeable fraction of patients with PDAC.Significance: Advanced PDAC is a malignancy with few treatment options that lacks molecular mechanism-based therapies. Our study uncovers recurrent gene rearrangements such as NRG1 fusions as disease-driving events in KRASwt tumors, thereby providing novel insights into oncogenic signaling and new therapeutic options in this entity. Cancer Discov; 8(9); 1087-95. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047.

[1]  E. Pleasance,et al.  Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Hofheinz,et al.  Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. von Kalle,et al.  Precision oncology based on omics data: The NCT Heidelberg experience , 2017, International journal of cancer.

[4]  Jürgen Weitz,et al.  Succession of transiently active tumor‐initiating cell clones in human pancreatic cancer xenografts , 2017, EMBO molecular medicine.

[5]  S. Fröhling,et al.  Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling , 2016, Leukemia.

[6]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[7]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[8]  A. Larsen,et al.  Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status , 2016, Targeted Oncology.

[9]  Kaoru Tanaka,et al.  The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer , 2015, Oncotarget.

[10]  A. Harris,et al.  Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer , 2015, Oncotarget.

[11]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[13]  L. Mileshkin,et al.  Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. , 2014, The oncologist.

[14]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[15]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[16]  V. Heinemann,et al.  KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer , 2013, Journal of Gastroenterology.

[17]  C. Sotiriou,et al.  Pertuzumab: new hope for patients with HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  U. Mansmann,et al.  EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 , 2012, British Journal of Cancer.

[19]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[20]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Michael C. Rusch,et al.  CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.

[22]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[23]  J. Shipley,et al.  Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study , 2009, American journal of clinical oncology.

[24]  K. Sekiguchi,et al.  Direct Binding of the EGF-like Domain of Neuregulin-1 to Integrins (αvβ3 and α6β4) Is Involved in Neuregulin-1/ErbB Signaling* , 2010, The Journal of Biological Chemistry.

[25]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[26]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[27]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[28]  M. Tsao,et al.  Human pancreatic duct epithelial cell model for KRAS transformation. , 2008, Methods in enzymology.

[29]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Iannitti,et al.  Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. , 2001, Cancer investigation.

[31]  Douglas L Falls,et al.  Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.

[32]  L. Cantley,et al.  Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer* , 2000, The Journal of Biological Chemistry.

[33]  L. Ailles,et al.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.

[34]  E. Peles,et al.  ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.